Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has presented positive research of GTI-2040 in pharmacokinetics in acute myeloid leukemia, showing high levels of the drug were present in patients.
Subscribe to our email newsletter
The research reports the uptake of GTI-2040 in distinct subcellular compartments of leukemic cells that exceeded plasma levels.
The data was consistent with previous findings, showing that GTI-2040 levels in circulating leukemic cells were 2.7 times higher and more sustained than values seen in plasma. The levels were even greater in leukemic blast cells in bone marrow, which is the primary target tissue in the treatment of leukemia.
“Direct measurement of the effects of GTI-2040 in leukemic blast cells can result in a better assessment of therapeutic benefit,” said Dr Aiping Young, president and CEO of Lorus. “We will continue to focus on target validation, including cellular uptake and activity of our drugs as part of our clinical development strategy.”
The pharmacokinetic studies with GTI-2040 presented in this study are part of an ongoing investigation of GTI-2040 combination therapy with cytarabine in patients with acute myeloid leukemia. These studies are conducted at Ohio State University and sponsored by the Cancer Therapy Evaluation Program of the US National Cancer Institute under a clinical trials agreement with Lorus.